Medifast Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Medifast şirketinin toplam hissedar öz sermayesi $205.3M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $293.5M ve $88.2M dir. Medifast 'in FAVÖK'ü $34.2M faiz karşılama oranı -7.2 dur. Şirketin $163.5M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	-7.2x
Nakit	US$163.51m
Eşitlik	US$205.28m
Toplam yükümlülükler	US$88.25m
Toplam varlıklar	US$293.53m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MED * 'nin kısa vadeli varlıkları ( $224.3M ) kısa vadeli yükümlülüklerini ( $75.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: MED * şirketinin kısa vadeli varlıkları ( $224.3M ) uzun vadeli yükümlülüklerini ( $13.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MED * borçsuzdur.

Borcun Azaltılması: MED * un 5 yıl önce borcu yoktu.

Borç Kapsamı: MED * un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: MED * şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Medifast Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Medifast, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

Medifast, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Medifast, Inc. to Report Q2, 2024 Results on Aug 05, 2024

Insufficient new directors

Insufficient new directors

Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Medifast, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Insufficient new directors

Insufficient new directors

Medifast Provides Earnings Guidance for the First Quarter of 2024

Medifast, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Lead Independent Director recently bought Mex$190k worth of stock

Third quarter 2023 earnings released: EPS: US$2.12 (vs US$3.30 in 3Q 2022)

Insufficient new directors

Medifast, Inc. Provides Earnings Guidance for the Full Year 2023

Medifast, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Insufficient new directors

Medifast, Inc. Announces Optavia Active Now Available

Medifast, Inc. Declares Quarterly Cash Dividend, Payable on November 7, 2023

Medifast, Inc. Provides Earnings Guidance for the Third Quarter 2023

Insufficient new directors

Insufficient new directors

Medifast Unveils New Product Line, Optavia Active

Medifast, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Insufficient new directors

Medifast, Inc. Declares Quarterly Cash Dividend, Payable on August 8, 2023

Medifast, Inc., Annual General Meeting, Jun 14, 2023

Medifast, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Medifast, Inc. Announces Quarterly Dividend, Payable on February 7, 2023

Medifast, Inc. Revises Earnings Guidance for the Year 2022

Medifast, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Insufficient new directors

Upcoming dividend of US$1.64 per share

Medifast Announces Quarterly Dividend, Payable on November 8, 2022

Insufficient new directors

Lead Independent Director recently bought Mex$10m worth of stock

Second quarter 2022 earnings released: EPS: US$3.45 (vs US$4.00 in 2Q 2021)

Insufficient new directors

Medifast, Inc. Revises Earnings Guidance for the Full-Year of 2022

Medifast Announces New Scientific Advisory Board Appointments

Medifast, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Insufficient new directors

Medifast, Inc.(NYSE:MED) dropped from Russell 2000 Dynamic Index

Medifast, Inc. Announces Quarterly Dividend, Payable on August 8, 2022

Insufficient new directors

Medifast, Inc. Revises Earnings Guidance for the Full-Year of 2022

Medifast, Inc., Annual General Meeting, Jun 15, 2022

Medifast, Inc. to Report Q1, 2022 Results on May 02, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Medifast, Inc. Provides Earnings Guidance for the Full-Year 2022

Medifast, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Insufficient new directors

Insufficient new directors

Insufficient new directors

Investor sentiment deteriorated over the past week

Independent Director recently sold Mex$3.1m worth of stock

Investor sentiment deteriorated over the past week

Medifast, Inc. Provides Earnings Guidance for 2021

Independent Director recently sold Mex$6.1m worth of stock

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS US$3.49 (vs US$1.57 in 1Q 2020)

Medifast, Inc. Announces Earnings Guidance for the Full Year 2021

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin